Holen Sie sich die Stockscreener-App
0.2949
0.32%
0.000949
Schlusskurs vom Vortag:
$0.294
Offen:
$0.294
24-Stunden-Volumen:
22,455
Relative Volume:
0.11
Marktkapitalisierung:
$9.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.67M
KGV:
-0.0955
EPS:
-3.09
Netto-Cashflow:
$-101.06M
1W Leistung:
+9.65%
1M Leistung:
-3.30%
6M Leistung:
-39.07%
1J Leistung:
-85.03%
1-Tages-Spanne:
$0.275
$0.30
1-Wochen-Bereich:
$0.2601
$0.3113
52-Wochen-Spanne:
$0.2195
$3.67
Athira Pharma Inc Stock (ATHA) Company Profile
Firmenname
Athira Pharma Inc
Sektor
Branche
Telefon
(425) 620-8501
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Vergleichen Sie ATHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.295 | 9.71M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.20 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.62 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
631.35 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.52 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
247.42 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-04 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-09-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-10-17 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-23 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Eingeleitet | BTIG Research | Buy |
| 2022-04-21 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Goldman | Neutral |
| 2020-10-13 | Eingeleitet | Goldman | Buy |
| 2020-10-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-13 | Eingeleitet | Jefferies | Buy |
| 2020-10-13 | Eingeleitet | Stifel | Buy |
Alle ansehen
Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com Canada
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa
SEC Form PRE 14A filed by Athira Pharma Inc. - Quantisnow
Athira Pharma stock hits 52-week low at $0.3 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.3 amid steep decline By Investing.com - Investing.com South Africa
What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News
Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks
Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.33 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks
Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN
Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire
Athira Pharma, Inc. SEC 10-K Report - TradingView
Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia
Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView
Can This Former Amgen VP Transform Terns Pharmaceuticals as New CFO? - Stock Titan
ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - Marketscreener.com
Molecular Partners (NASDAQ:MOLN) versus Athira Pharma (NASDAQ:ATHA) Head to Head Review - Defense World
Athira Pharma (ATHA) Expected to Announce Earnings on Thursday - Defense World
Alterity stock jumps on data for lead drug (ATHA:NASDAQ) - Seeking Alpha
Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth? - Yahoo Finance
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - MSN
Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m - Simply Wall St
Keeping Fraud Out of Research: Government Grant Whistleblower Awarded Over $200,000 - The National Law Review
Will Athira Pharma See A Boost From LIFT-AD Trial Results In Alzheimer's Research? - RTTNews
Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement - Being Patient
Athira to pay $4M to resolve research misconduct allegations - BioWorld Online
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 - MSN
Whistleblower Receives $200K After Alleging Scientific Research Misconduct - Whistleblower Network News
Bothell's Athira Pharma to pay $4M to settle falsified research claims - The Business Journals
Biotech company agrees to pay $4 million to settle data falsification allegations - Retraction Watch
Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud - Law360
Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act Allegations Related to Scientific Research - U.S. Politics Today
Athira Pharma to Pay $4 Million Over Alleged Research Misconduct - Marketscreener.com
Bothell pharma company to pay $4 million over falsified research claims - MSN
Athira Pharma Settles Claims of NIH Research Grant Misconduct - Bloomberg Law
Athira Pharma CEO sells shares worth $14,107 By Investing.com - Investing.com South Africa
Finanzdaten der Athira Pharma Inc-Aktie (ATHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Athira Pharma Inc-Aktie (ATHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jan 02 '25 |
Sale |
0.56 |
10,826 |
6,083 |
35,841 |
| Litton Mark James | President and CEO |
Dec 31 '24 |
Option Exercise |
0.00 |
108,333 |
0 |
267,698 |
| Litton Mark James | President and CEO |
Jan 02 '25 |
Sale |
0.56 |
25,107 |
14,108 |
242,591 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Dec 31 '24 |
Option Exercise |
0.00 |
36,667 |
0 |
139,271 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jan 02 '25 |
Sale |
0.56 |
8,510 |
4,782 |
130,761 |
| Renninger Robert | VP of Finance |
Dec 31 '24 |
Option Exercise |
0.00 |
12,359 |
0 |
92,605 |
| Renninger Robert | VP of Finance |
Jan 02 '25 |
Sale |
0.56 |
2,881 |
1,619 |
89,724 |
| Worthington Mark | General Counsel and CCO |
Dec 31 '24 |
Option Exercise |
0.00 |
36,667 |
0 |
92,245 |
| Worthington Mark | General Counsel and CCO |
Jan 02 '25 |
Sale |
0.56 |
8,510 |
4,782 |
83,735 |
1.36%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):